Animal-Origin-Free Cell Dissociation for Cell and Gene Therapy: What the Documentation Has to Cover

Animal-origin-free cell dissociation is easy to specify and hard to document. For a cell or gene therapy process, the enzyme that releases your cells is an ancillary material — it touches the product, it does not appear in the final formulation, and your regulator will nonetheless expect a file on it. Quality assurance will ask for that file long before process development finishes arguing about detachment times. This note sets out what it has to contain, which standards define it, what a current recombinant dissociation enzyme actually provides, and where the gaps still are.

Your dissociation enzyme is an ancillary material, not a consumable

The distinction is not semantic. A consumable is something you buy; an ancillary material is something you qualify. A reagent that contacts cells during manufacture but is not intended to be in the finished product is an ancillary material in US terminology, or a raw material of biological origin in European terminology — two names for the same obligation.

Reagents used during manufacture of a cell-based product but not intended to be present in the final product still carry risk — of adventitious agents, of residual carryover, and of lot-to-lot variability that propagates into your product's critical quality attributes. Reviews of cell-based product formulation have made the point that these “unintended components” are a recognised regulatory concern rather than an administrative footnote (Atouf, AAPS J 2016), and the same theme recurs in pharmaceutical-development assessments of cell-based medicinal products (Jere et al., J Pharm Sci 2020).

The underlying risk is well characterised. A US FDA investigation of vaccine-relevant cell lines stated plainly that animal-derived raw materials — cells, trypsin and serum — can be a major route for introducing viral contamination into biological products, following the detection of porcine circovirus type 1 sequences in rotavirus vaccines (Ma et al., Vaccine 2011). An industry consortium later pooled actual contamination events across biologic manufacturers to identify the most common contaminants and their sources, and drew explicit implications for emerging cell and gene therapies (Barone et al., Nature Biotechnology 2020). Going animal-origin-free does not by itself close that risk, but it removes one entry point and materially shortens the file you have to defend.

Alongside this sits the transmissible spongiform encephalopathy question. Source selection remains the primary control for TSE agents in biologicals, because robust clearance methods are still developing (Farshid et al., Curr Opin Biotechnol 2005). An animal-origin-free enzyme addresses this at source rather than by clearance — which is why an AOF/TSE-BSE declaration is the first document to ask for, not the last.

Practically, all of this means a dissociation enzyme needs a supplier file, a risk assessment, a specification you have agreed to, and a change-notification route — before it goes near a clinical batch.

Three frameworks your assessor will use — and they do not agree

Three documents govern ancillary materials for cell and gene therapy, and they are not interchangeable:

• Ph. Eur. 5.2.12 — Raw materials of biological origin for the production of cell-based and gene therapy medicinal products. The European general chapter; risk-based, and explicit about materials of biological origin.
• USP <1043> — Ancillary Materials for Cell, Gene, and Tissue-Engineered Products. The US general chapter, built around a risk-tiered qualification approach, so the depth of testing is driven by the material's risk and by how it is used, not by a fixed checklist.
• ISO 20399:2022 — Biotechnology — Ancillary materials present during the production of cellular therapeutic products and gene therapy products. The consolidated international standard, replacing the three-part ISO/TS 20399 series of 2018, and the one that splits the obligations between what the supplier should provide and what the user should assess.

On top of these sit the EU GMP guidelines specific to ATMPs, which make raw material control an explicit element of your own quality system.

A direct comparison of these guidelines found meaningful differences in scope and expectation between them (Tanaka et al., Cytotherapy 2022). The operational implication is simple: satisfying one does not automatically satisfy the others. If you file in both the EU and the US, check your supplier package against both chapters, not whichever one your supplier happens to cite.

The document pack: what to request before you qualify a dissociation enzyme

Use this as a request list to your supplier. If a supplier cannot produce these, the detachment data is irrelevant. The right-hand column shows what Kerry (formerly c-LEcta) publishes for CellTrypase as of PIS v4.0, so you can see the shape of a reasonably complete file — and where you still have to ask.

Five points about how to read those rows, each of which decides whether a document is worth having:

• “Animal-free formulation” is not the same claim as “no animal-derived material used anywhere in manufacture.” Insist on the second. A statement of origin should cover the fermentation medium and every downstream processing aid, not just what ends up in the bottle.
• The production strain is a GMO; the product should not be. PIS v4.0 states that the production strain is a genetically modified organism of safety level S1. Ask for written confirmation that the supplied product is not a live GMO, alongside the host organism and its biosafety classification.
• Quality system evidence means four specifics: which certification, issued by whom, covering which site, and valid until when. A logo is not a certificate.
• Ask for the analytical methods behind the specification, including the pharmacopoeial method used for sterility, endotoxin and mycoplasma. PIS v4.0 names them — Ph. Eur. 2.6.1 / USP <71>, LAL per Ph. Eur. 2.6.14 / USP <85> Method D, qPCR per Ph. Eur. 2.6.7, and Ph. Eur. 2.2.3 and 2.2.35 for pH and osmolality — which is more than many suppliers publish.
• The change notification commitment is the document most often forgotten and the one that hurts most later. Get the site and country of manufacture in writing at the same time, and confirm the certificate is site-specific and current.

One further caution when you read the release specification itself: activity is controlled to a two-fold window at both concentrations — 0.6–1.2 kU/L at 1x and 6–12 kU/L at 10x. Two in-specification lots can therefore differ enough to shift detachment time. That is a reason to fix your incubation by observation rather than by a single validated clock.

What the performance data covers — and what it does not

Documentation completeness and performance evidence are different things, and it is worth being blunt about the second. The Product Information Sheet reports application data for four production cell lines:

Source: CellTrypase Product Information Sheet v4.0 (Kerry, 18 August 2026). The MDCK release time is roughly ten times that of HEK 293 — shown here because you need it for scheduling, not despite it.

That table is no longer the whole evidence base. Human iPSC data is now published. In 2D colonies, 1× CellTrypase reached a single-cell suspension in 5 minutes against 7 minutes for the industry-standard control, with 94% viability for both enzymes, 99% relative yield, residual aggregates below 5%, and pluripotency markers (Oct3/4, SSEA4, TRA-1-60, CD30, Nanog, Sox2, SSEA3) above the 75% acceptance threshold by flow cytometry. In 3D iPSC aggregates both enzymes took about 10 minutes; CellTrypase gave 87% viability against 85%, 104% relative yield and fewer residual aggregates (12% against 16%).

Serial passaging is covered too. Kerry has since published five-passage data (P0–P4) for CHO-K1, HEK 293, MDCK and Vero, covering viability, relative yield and population doubling time. Doubling times were equal to or shorter than the industry-standard control on all four lines, so proliferation is maintained over serial passaging rather than merely assumed.

Source: Kerry scientific poster #11462, “Advancing cell dissociation in bioprocessing with CellTrypase” (February 2026); n = 3 technical replicates, mean ± SD.

For a cell and gene therapy audience, the honest statement is now narrower but still worth making: published comparative data covers CHO-K1, HEK 293, MDCK, Vero and human iPSC in 2D and 3D. Everything else carries no published figures. Organoids, primary cells and hESC are named by the manufacturer as intended applications; MSC, T cells, neurons, cardiomyocytes and RPE are not named at all — and neither group carries figures. No surface-epitope retention data is published for any cell type.

Two further gaps are worth naming, because they are the ones a filing will expose. PIS v4.0 gives no long-term stability beyond the 21-month claim, and it contains no head-to-head comparison against any named commercial reagent — so no equivalence claim against a competing product can be made from it, and none is made here.

Fuller data, including the differentiated 3D iPSC work, is in the CellTrypase Application Note v1.1, which Kerry supplies on request — request it here. If a supplier claims coverage beyond what is published, ask which study, which passage, which assay. For a CAR-T or MSC process, surface-marker retention after dissociation is a release-relevant attribute, and it is not something to take on trust from a datasheet that does not measure it.

R&D grade or GMP grade, and what EXCiPACT actually certifies

CellTrypase is supplied in two grades from the same manufacturing platform: R&D grade under ISO 9001:2015 — a general quality management standard, appropriate for research and early process development — and GMP grade under EXCiPACT® GMP/GDP certification, an independent third-party certification scheme for pharmaceutical excipient manufacture and distribution. The attraction is obvious: develop on the cheaper grade, transfer to the certified grade for clinical manufacture, and keep the enzyme constant across the transition. The practical sequencing for most programmes is to develop and screen on R&D grade — currently listed at $32.00 for the 100 mL 1x format (cat. 22103-1X-100) — then move to GMP grade (cat. 22103-1X-100-G) for tech transfer and clinical manufacture.

Three cautions, all real.

First, EXCiPACT certification is evidence about the supplier, not about you. It speaks to the supplier's manufacturing and distribution controls. It is not a marketing authorisation, and it does not certify your process.

Second, a grade change is still a change. Substituting an ancillary material — even for a nominally identical product at a higher grade — is a change-control event that your quality system governs. No supplier statement can waive your own comparability assessment, and you should be suspicious of any that appears to. The scale of the exercise is proportionate to risk, not automatically large, but it is never zero.

Third, plan the comparability work rather than assume it. There is precedent for doing this properly: a published case study transitioning an MSC expansion process from research-use-only to GMP-grade ancillary material demonstrated no statistically significant differences in harvest yield, doubling time, seeding efficiency or fold expansion, and confirmed ISCT marker criteria after transfer (Frank et al., Cytotherapy 2025). Note what that study did: it measured equivalence rather than asserting it. That is the model to copy.

Related to this, be aware of the concentration formats. The 10x concentrate is materially cheaper per millilitre of working solution, but diluting it adds an open manipulation and a diluent you must qualify. In a GMP suite that trade-off often favours the ready-to-use 1x format despite the higher unit price.

What a supplier can and cannot do for your change control

A supplier can give you specifications, certificates, stability data, an origin statement and a change notification commitment. A supplier cannot decide the scope of your revalidation, and any vendor claiming that switching reagents needs “no revalidation” is describing their own paperwork, not your quality system. Change control belongs to the licence holder.

What a defensible bridging package usually contains:

• A written comparability protocol agreed before the first run, with pre-defined acceptance criteria.
• At least three consecutive passages or runs on the actual cell type, vessel format and medium you use — not a demonstration on a convenient line.
• Endpoints that include your critical quality attributes, not just detachment time: viability, viable yield, identity and potency markers, and product-specific attributes such as vector genome titre or transduction efficiency.
• A recorded risk assessment referencing USP <1043> or Ph. Eur. 5.2.12 tiering, showing why the depth of qualification you chose is appropriate.

The reason to insist on real data rather than assumed equivalence is that reagent and medium changes do measurably move product attributes in cell therapy manufacture. In a recent CAR-T study, moving to serum/xeno-free medium in stirred-tank bioreactors changed transduction efficiency, growth kinetics and the CD4:CD8 ratio at harvest relative to serum-containing medium (Silva Couto et al., Biotechnol J 2025). The direction of change there was favourable; the point is that it was not neutral, and it was only visible because it was measured.

A practical qualification sequence

1. Request the document pack from the table above, including the two items marked “request from supplier”. Note what arrives and what does not.
2. Map the file against your filing regions — Ph. Eur. 5.2.12 and USP <1043> expect different things; ISO 20399:2022 helps you frame the supplier conversation.
3. Run a bench comparison on your own cells. A free 100 mL sample is available for qualification and process development. Record release time, viability, recovered cell number, and the endpoints that matter for your product — marker expression, potency, and behaviour over the following two passages.
4. Confirm at scale-down in your actual vessel format before committing.
5. Raise the change control, with the comparability data attached. Agree the change-notification scope with the supplier in writing at the same time.

Dosing carries over directly — approximately 1 mL per 25 cm², pre-warmed, with activity quenched by dilution in buffer or medium rather than by a separate inhibitor. If you are replacing an existing ready-to-use recombinant dissociation reagent, 1:1 volume substitution is a reasonable starting point for planning. Treat both as dosing guidance only: verify detachment time and viability in your own cell model before switching.

Questions to send the supplier before you qualify the material

1. Can you supply a lot-specific CoA against a fixed release specification, and how long are retained samples kept?
2. Does the animal-origin-free statement cover the fermentation medium and all downstream processing aids, or only the final formulation?
3. What is the site of manufacture, and is the EXCiPACT certificate site-specific and current?
4. Will you sign a change notification agreement, and what notice period applies?
5. What long-term stability work is ongoing, and when will data beyond the current 21-month claim be released?
6. Is a regulatory support file or drug master file available to reference in a submission?
7. What data, if any, exists for my cell type — and if none exists, will you say so in writing?

Question 7 is the one that separates a supplier from a sales pitch. For CellTrypase, the honest answer for organoids, primary cells, hESC, MSC, T cells, neurons, cardiomyocytes and RPE is that no performance data is published for any of them. That is why the sensible next step is a trial rather than a claim. The R&D grade is available as a free 100 mL sample for that purpose, and GMP-grade quantities and documentation packages can be arranged through a quote request.

For the handling detail, see the CellTrypase dissociation protocol; for the full attribute list, the CellTrypase specification guide. Cell models are listed under cell lines.

References

1. Tanaka M, et al. Comparison of guidelines for biological ancillary materials used for the manufacture of gene and cellular therapy products. Cytotherapy 2022. doi:10.1016/j.jcyt.2022.09.005
2. Atouf F. Cell-based therapies formulations: unintended components. AAPS J 2016. doi:10.1208/s12248-016-9935-9
3. Jere D, et al. Challenges for cell-based medicinal products from a pharmaceutical product perspective. J Pharm Sci 2020. doi:10.1016/j.xphs.2020.11.040
4. Ma H, et al. Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines. Vaccine 2011;29(46):8429–37. doi:10.1016/j.vaccine.2011.07.123
5. Barone PW, et al. Viral contamination in biologic manufacture and implications for emerging therapies. Nat Biotechnol 2020;38(5):563–572. doi:10.1038/s41587-020-0507-2
6. Farshid M, et al. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals. Curr Opin Biotechnol 2005;16(5):561–7. doi:10.1016/j.copbio.2005.07.006
7. Frank ND, et al. Good Manufacturing Practice-grade fibronectin for hollow-fiber bioreactor cell manufacture: a mesenchymal stromal cell case study. Cytotherapy 2025;27(3):391–9. doi:10.1016/j.jcyt.2024.11.011
8. Silva Couto P, et al. Process development for CAR-T cell manufacturing in stirred-tank bioreactors under serum/xeno-free conditions. Biotechnol J 2025. doi:10.1002/biot.70114
9. European Pharmacopoeia general chapter 5.2.12, Raw materials of biological origin for the production of cell-based and gene therapy medicinal products.
10. USP General Chapter <1043>, Ancillary Materials for Cell, Gene, and Tissue-Engineered Products.
11. ISO 20399:2022, Biotechnology — Ancillary materials present during the production of cellular therapeutic products and gene therapy products.
12. European Medicines Agency. Guidelines relevant for advanced therapy medicinal products (ATMPs).
13. c-LEcta GmbH (a Kerry company). Product Information Sheet, CellTrypase v4.0, valid as of 18 August 2026.
14. Kerry. Scientific poster #11462, Advancing cell dissociation in bioprocessing with CellTrypase, February 2026.

About the figures: Figures 1–4 are illustrative summaries prepared by BioHippo from the CellTrypase Product Information Sheet v4.0, the Kerry scientific poster, published standards and the cited literature. They are not experimental data, and no viability, recovery or comparison figure is implied beyond what the cited source documents state.
Data source: Product figures are taken from the CellTrypase Product Information Sheet v4.0 (Kerry, 18 August 2026) and Kerry scientific poster #11462 (February 2026). Literature identified via PubMed. Pharmacopoeial and ISO chapters are cited by title and linked to the issuing body; consult the current official text for binding requirements. Prices are the BioHippo list price at the time of publication and may change.
Research use statement: CellTrypase R&D grade (cat. 22103-1X-100 and related formats) is supplied For Research Use Only (RUO) and is not for use in diagnostic or therapeutic procedures. GMP-grade material is supplied as a processing aid and manufacturing raw material under EXCiPACT® GMP/GDP certification, is not for direct administration to humans or animals, and it remains the user's responsibility to qualify any material for its intended use.
Trademark notice: TrypLE™ is a trademark of Thermo Fisher Scientific Inc. Any reference is nominative and for identification or comparison only; no affiliation with, sponsorship by, or endorsement from the trademark owner is implied.